Does Medicaid Cover GLP-1 Medications? How to Check Your State and What to Do Next

Two Different Questions: Which Use, and Which State

People often ask "Does Medicaid cover Ozempic?" as if there were one national answer. There isn't. Medicaid is run by each state within federal rules, and those rules treat GLP-1 medications differently depending on what they are prescribed for.

Under the Medicaid Drug Rebate Program, state Medicaid programs must cover nearly all FDA-approved drugs from participating manufacturers for medically accepted indications. Drugs used for weight loss are in a small group that federal law allows states to exclude. KFF summarizes the result this way: coverage of GLP-1s for obesity treatment is optional for states, while coverage is required for drugs approved to treat diabetes and, since March 2024 and December 2024 respectively, for cardiovascular disease risk reduction (Wegovy) and moderate to severe obstructive sleep apnea in adults with obesity (Zepbound). KFF also notes that coverage is required when deemed medically necessary for children under Medicaid's Early and Periodic Screening, Diagnostic and Treatment (EPSDT) benefit.

"Required" doesn't mean automatic. States commonly use utilization controls such as prior authorization, step therapy and preferred-drug lists, so your prescriber may need to document the diagnosis or choose the product your state prefers.

State Coverage for Weight Loss Has Been Shrinking

The state-by-state picture has moved quickly. KFF's 2025 Medicaid budget survey found 16 state programs covering GLP-1s for obesity treatment as of October 2025. On January 1, 2026, California, New Hampshire, Pennsylvania and South Carolina stopped covering them for obesity in adults, while continuing to cover them for other conditions such as type 2 diabetes. North Carolina eliminated its coverage in October 2025 during a budget stalemate and reinstated it in December 2025. That left 13 states as of January 2026, by KFF's count, and KFF reported that several other states were planning or considering restrictions. State budget decisions since then have continued to change the list.

Because the list changes with state budgets, we don't publish a state-by-state coverage table here. A list that was right in January can be wrong by July. The reliable source is your own state Medicaid agency or your managed care plan, checked close to when you need the prescription filled.

What a coverage change usually looks like for a patient

When a state ends weight-loss coverage, people who already have a prior authorization approved for that use may find it isn't renewed, or a refill is rejected after the effective date. If you get a notice from your state or plan about a change, read it for the effective date and the reason, and call your prescriber's office early. They may need to review whether another covered diagnosis applies, which is a clinical decision for them to make, or help you plan for the gap.

The BALANCE Model: What It Is and What It Isn't

In 2026 CMS launched the BALANCE Model (Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth), a voluntary demonstration run by the CMS Innovation Center. CMS negotiated prices and coverage terms for select GLP-1 medications with Eli Lilly and Novo Nordisk on behalf of state Medicaid agencies and Medicare Part D plans that choose to participate. According to CMS and KFF:

• State Medicaid agencies could join on a rolling basis from May 1, 2026 through January 1, 2027, and the application deadline for states was July 31, 2026.
• Participating states adopt standardized coverage criteria, which they can make broader but not more restrictive, and the terms apply in both fee-for-service Medicaid and Medicaid managed care.
• KFF lists the model drugs as all formulations of Foundayo, Mounjaro, Ozempic, Rybelsus and Wegovy, and the KwikPen formulation of Zepbound.
• The model doesn't change what Medicaid enrollees pay out of pocket, which federal law limits to nominal amounts.
• Manufacturers will offer lifestyle support programs to people in the model; KFF noted that details were not yet available when it last updated its brief.
• CMS says coverage depends on state and manufacturer participation and "this model will not guarantee coverage for any individual."

On July 30, 2026, Indiana's governor announced that the state's Medicaid program would participate, with eligibility criteria and timing to be announced as the agreement was finalized. Other states' decisions may not be announced in the same way, so the practical step is the same as always: ask your state Medicaid agency or plan whether it participates and when coverage starts.

The Medicare side of the same initiative has gone differently. CMS delayed the Medicare Part D portion of BALANCE indefinitely and extended a separate program, the Medicare GLP-1 Bridge, through the end of 2027. Our Medicare GLP-1 guide covers that program.

How to Check What Your Medicaid Plan Covers

1. Find out how you get your Medicaid benefits. Your member ID card will usually show whether you are in a managed care plan (a named health plan) or fee-for-service Medicaid run directly by the state. Many states use managed care for most enrollees, and the plan's formulary is what you check.
2. Look up the drug list. States publish a preferred drug list (PDL), and managed care plans publish formularies. Search for the specific product name your prescriber mentioned, and look for notes such as "PA" (prior authorization), "ST" (step therapy) or quantity limits.
3. Call member services. The number is on your card. Use the questions below and write down the date, the name of the person you spoke with and what they said.
4. Let your prescriber's office handle the prior authorization. The prescriber submits the request with the clinical documentation the plan asks for. Our prior authorization guide explains the process and how to track it.
5. Put the renewal date on your calendar. Approvals often expire. A lapsed authorization is one of the most common reasons a refill gets rejected at the pharmacy counter.

Questions to ask Medicaid member services

• Is [drug name] on the formulary or preferred drug list, and for which diagnoses?
• Does it require prior authorization, step therapy or a quantity limit?
• Is there a preferred product in this class that the plan covers with fewer requirements?
• Does our state participate in the CMS BALANCE Model, and if so, when does coverage start?
• Are any coverage changes scheduled for this drug in the next plan year or state fiscal year?
• Which pharmacies are in network, and can the prescription be filled by mail?
• If the request is denied, how do I file an appeal, and what is the deadline?

If You're Denied: Appeals and Fair Hearings

A denial isn't necessarily the end. Ask for the decision in writing, with the reason. Federal Medicaid rules then give you a path that depends on how you receive benefits:

• Medicaid managed care: Under 42 CFR 438.402, you have 60 calendar days from the date on the plan's adverse benefit determination notice to file an appeal with the plan. If the plan upholds the denial, you can then request a state fair hearing, generally within 120 days of the plan's appeal decision under 42 CFR 438.408.
• Fee-for-service Medicaid: You can request a state fair hearing under the federal fair hearing rules in 42 CFR Part 431, Subpart E. The state sets the request deadline, which may not exceed 90 days from the date the notice is mailed.

A denial because the state doesn't cover the drug for weight loss at all is different from a denial because paperwork was missing or criteria weren't documented. The first is a policy decision that an appeal usually can't change; the second often can be fixed. Our guide to appealing a GLP-1 insurance denial covers how to organize the paperwork and what to ask your prescriber for.

If You Have Both Medicare and Medicaid

People who are dually eligible for Medicare and Medicaid get their prescription drug coverage through Medicare Part D, so Medicare's rules apply to GLP-1 prescriptions. Medicare has been prohibited by law from covering drugs used specifically for weight loss, but Part D covers GLP-1s for other medically accepted uses, and the temporary Medicare GLP-1 Bridge offers a $50 monthly copayment for eligible obesity prescriptions from July 1, 2026 through December 31, 2027. KFF notes that Low-Income Subsidy cost-sharing help does not apply to the Bridge copayment. See our Medicare GLP-1 guide for eligibility and how it works.

Other Situations That Affect Medicaid Coverage

Moving to another state

Medicaid doesn't transfer between states. You apply in the new state, and its coverage rules for GLP-1s may be very different. Plan the timing of refills and a new prior authorization before you move; our moving guide has a checklist.

Losing Medicaid or switching coverage

If you lose Medicaid eligibility or move to employer or marketplace coverage, the new plan has its own formulary and prior authorization. Our guide to insurance changes covers what to line up before the switch, and our open enrollment guide explains how to compare plans.

Paying out of pocket

Manufacturer copay savings cards generally exclude people with Medicaid and other government coverage, as our manufacturer savings guide explains. Manufacturers and some federal initiatives have announced direct-to-consumer cash prices for certain products; those offers and their terms change, so confirm the current price and eligibility directly with the program before you rely on it. Avoid unregulated online sellers; see how to check for counterfeit GLP-1 pens.

What This Guide Does Not Cover

We don't tell you whether a GLP-1 medication is right for you, which product to use, how to dose it, or how well any medication works. Whether another covered diagnosis applies to you is a clinical judgment for your prescriber, not something to work out from a coverage list. For coverage questions about your specific plan, your state Medicaid agency or plan member services has the final answer.

Sources

• KFF: Medicaid Coverage of and Spending on GLP-1s (required vs. optional coverage, EPSDT, 16 states in Oct. 2025 and 13 in Jan. 2026)
• KFF: What to Know About the BALANCE Model for GLP-1s in Medicare and Medicaid and the Medicare GLP-1 Bridge (updated May 11, 2026)
• KFF Health News: California Ends Medicaid Coverage of Weight Loss Drugs (California, New Hampshire, Pennsylvania and South Carolina, Jan. 1, 2026)
• CMS: BALANCE Model overview and FAQ
• CMS: Innovation Insight, BALANCE Model RFAs (March 9, 2026)
• State of Indiana: Governor Braun announces Medicaid participation in BALANCE (July 30, 2026)
• 42 CFR Part 438, Subpart F: Medicaid managed care grievance and appeal system
• 42 CFR Part 431, Subpart E: Fair hearings for applicants and beneficiaries

Frequently Asked Questions